Original language | English |
---|---|
Pages (from-to) | 416-426 |
Number of pages | 11 |
Journal | Catheterization and Cardiovascular Interventions |
Volume | 98 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2021 |
Externally published | Yes |
Keywords
- blood pressure
- cardiovascular risk
- device-based hypertension therapies
- hypertension
- renal denervation
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Catheterization and Cardiovascular Interventions, Vol. 98, No. 3, 09.2021, p. 416-426.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Renal denervation in hypertension patients
T2 - Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF
AU - Kandzari, David E.
AU - Townsend, Raymond R.
AU - Bakris, George
AU - Basile, Jan
AU - Bloch, Michael J.
AU - Cohen, Debbie L.
AU - East, Cara
AU - Ferdinand, Keith C.
AU - Fisher, Naomi
AU - Kirtane, Ajay
AU - Lee, David P.
AU - Puckrein, Gary
AU - Rader, Florian
AU - Vassalotti, Joseph A.
AU - Weber, Michael A.
AU - Willis, Kerry
AU - Secemsky, Eric
N1 - Funding Information: George Bakris: Consultant for Merck, Bayer, Vascular Dynamics, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, Horizon, Novo Nordisk; Steering committee of trials supported by Bayer, Vascular Dynamics, Quantum Genomics, Alnylam and Novo Nordisk. Jan Basile: Consultant for Medtronic; Research grants from Eli Lilly, ReCor, and Ablative Solutions; Royalties from UpToDate. Michael J. Bloch: Consultant/Honoraria from Recor, Medtronic, Amgen, Esperion, Janssen, Amarin, and Bristol Meyers Squibb; Research Support from Recor. Debbie L. Cohen: Research support from Medtronic and ReCor. Cara East: Research support from Medtronic. Keith C. Ferdinand: Consultant for Amgen, Novartis, and Medtronic. Naomi Fisher: Consultant for Aktiia; Consultant and research support from Recor Medical. David E. Kandzari: Consulting honoraria from Cardiovascular Systems, Inc, Medtronic. Institutional research/grant support from Ablative Solutions, Boston Scientific, Biotronik, Cardiovascular Systems, Medtronic, Orbus Neich, and Teleflex. Ajay Kirtane: Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Neurotronic. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for consulting and/or speaking engagements in which Dr. Kirtane controlled the content. Personal: Consulting from IMDS; Travel Expenses/Meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron. David P. Lee: Consultant for Medtronic and DeepQure; Research grants from Medtronic and Ablative Solutions. Florian Rader: Consultant for Recor, Medtronic, and MyoKardia. Eric Secemsky: Consulting/Speaking: Abbott, Bayer, BD, Boston Scientific, Cook, CSI, Inari, Janssen, Medtronic, Philips, and VentureMed; Research grants from NIH/NHLBI K23HL150290, Harvard Medical School's Shore Faculty Development Award, AstraZeneca, BD, Boston Scientific, Cook, CSI, Laminate Medical, Medtronic, and Philips. Raymond R. Townsend: Consultant for Medtronic, Axio, Regeneron, Ionis, and IMEDIC; Royalties from UpToDate; Grants from NIH. Joseph A. Vassalotti: Consultant for RenalytixAI, plc. Michael A. Weber: Consultant to Medtronic, ReCor, Ablative Solutions, Johnson & Johnson, Urovant, and Omron. Kerry Willis and Gary Puckrein have no conflicts to disclose. Funding Information: The present communication represents considerations and consensus views from a roundtable discussion between leaders in hypertension and interventional cardiology. The consensus conference was supported by the National Kidney Foundation and the Society for Cardiovascular Angiography and Interventions; however, the content of this report represents solely the opinions of the consensus committee members.
PY - 2021/9
Y1 - 2021/9
KW - blood pressure
KW - cardiovascular risk
KW - device-based hypertension therapies
KW - hypertension
KW - renal denervation
UR - http://www.scopus.com/inward/record.url?scp=85111850161&partnerID=8YFLogxK
U2 - 10.1002/ccd.29884
DO - 10.1002/ccd.29884
M3 - Article
C2 - 34343406
AN - SCOPUS:85111850161
SN - 1522-1946
VL - 98
SP - 416
EP - 426
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 3
ER -